PDCD1 and neoplasm: Moreover, in recent years, immunotherapeutic drugs such as nivolumab, pembrolizumab (targeting PD-1) or atezolizumab (targeting PD-L1) have been approved as standard therapeutic treatment options in NSCLC depending on the tumor’s molecular subtype [1,27].